Member Info for DugWalker

"Oxford BioDynamics PLC on Monday launched a strategic review after warning it would need additional cash resources by early 2025".

Laura.

The above is from the jorses mouth, what's your thoughts?

Mate she's providing genuine entertainment . Reminds me of Burrows trying to appear knowledgeable by reading a press release from a crib sheet. So sadly ill-informed they are tragically comedic.

Not as wise as your subtle fishing for share tips. 👍

Laura I bought a company with breakthrough technology that should already be earning them a fortune were it not for inept management. I bought it as a high risk high potential reward investment as part of a balanced portfolio and at a level I vould afford to lose. As it happens I didn't lose much anyway because I baled as soon as it became apparent they were not going leverage the opportunity of the Transform project.

You seem desperate to imagine that posters have held OBD as their sole investment and are now homeless as a result. It's comical that you think your jibes will stop anyone commenting on the abject management of the company so you can try to persuade others to buy in the hope you make a few %.

Have you figured out why an investment company files uncosolidated financial statements yet? 😉

If you think I bought without doing research and understanding the risks then your even dumber than you seem. My issue with OBD is the incompetence of the management so I'll hang around to warn potential investors in case they are tempted by the ill-informed tripe spouted by pump and dump merchants. 😉

Laura.

Can I suggest you spend the rest of your evening on more rewarding pursuits?

Foŕ example go investigate the difference between consolidated and unconsolidated accounts. 🤣

So in addition to not understanding OBD's commercial update RNS, you don't grasp the concept of an investment company having consolidated and u consolidated accounts.

🤣

With the company suggesting productin anticipated around end of the month news on the deeper drill can't be far off. Is this the week?

An article specifically discussing merger and acquisition activity involving mcap companies has no relevance whatsoever to an AIM traded minnow like OBD.

It may also prove educational for you to actually read the recent commercial update RNS which contains the following statement from the BoD.

"Currently, the strategic review does not envisage an offer for the Company under the City Code of Takeovers and Mergers".

10 weeks is a long time, just imagine a company telling you they could sell unvalidated tests for a couple of years, they should be market leaders by now, right ?

How is your Nan?

Ice.

Smart move. With only 10 weeks till they run out of money suggest you wait till the SP hits 0.6p. It'll all be about getting lucky with the timing of your buy but it's going lower...😉

Not that tired old chestnut Laura. 🤣

It is entirely legitimate that people knowledgeable of this company post in here regardless of whether they are current shareholders or not. It might help prospective investors avoid getting their fingers burned. It's a strange philosophy that wants to silence people when you explicitly acknowledge the validity of their comments.

Burrows has been pushing the concept of commercial partnerships on specific tests for quite some time. The veterinary test being one recent example where he promised such an agreement would avoid further dilutive placings.

Reality is none of the tests are validated and until they are no company will risk its reputation by using them. A commercial partnership isn't riding to the rescue here.

As for the pipeline of projects. It's again very impressive. but it has simply led to the unsustainable burn rate that has brought the company to its knees.

I suggest you new posters that have suddenly discovered OBÐ do some research on the trials required to validate CirT, PSE or the other pipeline tests, specifically investigate the costs. Had Burrows acted on his belief that participation in the Transform trial was 'critical' he might have had those costs paid for the PSE test, but we all know how that panned out.

That

Wouldn't get too excited about that Laura. After all the company has been pushing the following narrative for a very long time.

"Oxford Biodynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsibushi Tanabe Pharma".

Impressive though that seems it hasn't helped OBD reach commercial viability or validate their tests beyond the laboratory. I doubt this latest partnership will be the exception

Icecool you are utterly clueless as to who traded 'in volume'. There has been no TR1 announcement since Lombards several days ago. Your 'factual' posts are based on nothing more than conjecture and speculation designed to pump so you and your mates can dump. . Given that the SP was down another 4% today the trading volumes were down to selling not to people 'taking positions'. I can tell facts and logic are not your strong points 🤣

Your opinion based on what? What is the information that leads you to your opinion? 😂

😂

I don't know and don't care if Lombard are in, out or shaking it all about. What I do know is it's idiocy to

state something is 'clearly' a fact 'in your opinion'.

....in icecool's "opinion'.

😂 I just love this kind of idiocy.

So when you started a thread entitled 'FOMO FRiday' in which your first comment was Today's the day' you meant next Friday is the day. 🤣

Rofl.

They have 'been in talks with BUPA, with London Clinics and numerous US medics for years but they still have not realised the need for proper medical trials and validation. Talks are just hot air with no impact on the bottom line. Contracts count but they don't have any of those.